Details
Nemotan Indications
After previous infusion Nemotan®, solution for infusion, for the treatment and prevention of ischemic neurological disturbances caused by vasospasm brain after subarachnoid hemorrhage due to aneurysm rupture.
Contraindications
Use of the drug Nemotan contraindicated in case of individual hypersensitivity to nimodipine or any other drug.
Use of the drug Nemotan, tablets, film-coated membrane, in combination with rifampicin or antiepileptic drugs (phenobarbital, phenytoin, carbamazepine) is contraindicated as concurrent use of drugs leads to a significant reduction of efficacy of Nimotop
Dosage & Administration
After previous infusion therapy with Nemotan, which lasted from 5 to 14 days, prescribed a daily dose of 6 times a day 2 tablets, film coated membrane (6x60 mg nimodipine).
In case of adverse reactions the dose should be reduced, if necessary - to stop the drug.
In the case of a related treatment along with drugs inducing or inhibiting cytochrome system P450 3A4, may require dose adjustment (see. Section "Interaction with other medicinal products and other forms of interaction").
Patients with hepatic impairment
In case of serious disturbances of liver function, particularly liver cirrhosis, the bioavailability of nimodipine can increase due to lower first-pass effect and reduced metabolic clearance. The action of the drug and the adverse reactions, such as hypotension, these patients may be more pronounced.
In such cases, reduce the dose or, if necessary, consider stopping treatment.
